Durata Therapeutics

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Durata Therapeutics, established in 2009 in Morristown, New Jersey, is a clinical development stage pharmaceutical company which focuses on the treatment of infectious diseases. The company acquired dalbavancin, a long-acting semisynthetic lipoglycopeptide antibiotic, from Pfizer in December 2009.[1] Durata has initiated two Phase III studies of dalbavancin for intravenous (IV) treatment of acute bacterial skin and skin structure infections.[2] In 2012, the company moved its global headquarters from Morristown to Chicago in a deal with $2 million in tax credits.[3] In October 2014 Durata was acquired by Actavis for about $675 million.[4]

References[edit]

External links[edit]